参考资料:
[1]Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study,Published:February 14, 2022
[2]Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,Published:December 21, 2021
[3]Ministerio de Salud丨Chile realiza primer estudio a nivel mundial sobre uso de dosis de refuerzo en vacunas inactivadas: Aumenta efectividad en prevención y hospitalización por COVID-19
[4]Pan HX, Wu QH, Zeng G, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medrxiv. 2021.07.23.21261026v1.
[5]Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,September 2, 2021,N Engl J Med 2021; 385:875-884,DOI: 10.1056/NEJMoa2107715
[6]新华社丨智利研究称加强针可大幅提高新冠疫苗有效率
[7]王长征. 新型冠状病毒肺炎疫苗研究开发现状和面临的挑战[J]. 国际呼吸杂志,2021,41(17):1281-1285. DOI:10.3760/cma.j.cn131368-20210323-00227.
[8] 陈维刚. 新冠疫苗是怎样提供保护作用的[J]. 保健与生活,2021(21):38-39.
版权声明:内容来源于互联网和用户投稿 如有侵权请联系删除